BOSTON CELL STANDARDS INC
FY24 SBIR PHASE II RD CONTRACT - TOPIC 442 BOSTON CELL STANDARDS, INC.
FY24 SBIR PHASE II RD CONTRACT - TOPIC 442 BOSTON CELL STANDARDS, INC. is a funding opportunity from BOSTON CELL STANDARDS INC, up to 1995119, closing September 15, 2026.
Sep 15, 2026
(46d left)Overview
200 WORDS. "The treatment that a cancer patient receives should not depend on which laboratory performs the test." The objective of this project is to make that statement a reality. Immunohistochemistry (IHC) testing of cancer biopsies is important for both accurate diagnosis and appropriate treatment. The absence of…